X
Pharma Advancement
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

    Clinical Development

    AI Revolutionizing Drug Discovery and Clinical Development

    Drug-Development

    China’s Super Me-Too Drug Development: A New Pharma Frontier

    Omics Based Clinical Trials

    Asia Pacific Omics-Based Clinical Trials Market Growth

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

    Clinical Development

    AI Revolutionizing Drug Discovery and Clinical Development

    Drug-Development

    China’s Super Me-Too Drug Development: A New Pharma Frontier

    Omics Based Clinical Trials

    Asia Pacific Omics-Based Clinical Trials Market Growth

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home IPR Data Management

Microbial Fermentation Tech Market To Go Beyond $56b In 2023

Content Team by Content Team
12th April 2023
in IPR Data Management, News
Silverback Therapeutics Raises $78.5 Million to Advance Cancer Antibody Conjugates for Solid Tumors

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

The worldwide microbial fermentation technology market is anticipated to overshoot a value of $57,974.87 million by 2033, as per a report.

Hence, the projected compound annual growth rate is going to be 5.7% by 2033. In the years that have gone by, the microbial fermentation technology sector has experienced significant growth. Taking this into consideration, the market is expected to reach a value of $32,729.05 million in 2023.

The major drivers of this sector include advancements in bioprocessing, the creation of novel microbial strains used for the production of high-value compounds, and rising demand for biopharmaceutical products like enzymes and antibiotic vaccines.

As of now, one of the major challenges for the sector is a high research and development cost, as well as limited access to raw materials. Besides, a strict regulation on the usage of microbial fermentation technology also hampers the progress of the sector.
Yet, innovative approaches like strategic partnerships can help navigate the challenges, as per the market report.

One of the important trends that is being seen currently is the elevated adoption of single-use bioreactor systems. These happen to be more cost-effective as well as flexible when compared to the traditional bioreactors made of stainless steel.

In totality, the report has gone on to identify a continuing trend when it comes to environmentally friendly production processes, which include higher demand as far as bio-based products are concerned.

Yet another trend that is observed, as per the report, is the increased use of AI and machine learning in terms of the microbial fermentation process. One of the benefits of these technologies is their built-in ability to help lower production costs.

There is an increasing trend when it comes to the production of biologics and biosimilars as well. A higher rate of outsourcing of biologics manufacturing to CROs or CDMOs, in all possibilities is expected to surge the market growth in the forecast period.

All said and done, the biopharmaceutical companies are anticipated to earn a 41% market share in 2023, whereas the recombinant protein segment is expected to have a 33% market share this year.

It is well to note that the US is projected to dominate the microbial fermentation technology segment, with a whopping share of 30% in the forecast period. Germany, on the other hand, is expected to have a market pie of 20% within the same period. Significantly, the trend towards personalised medicine as well as biologics is anticipated to drive the market there. Furthermore, when it comes to China, the market there is expected to grow significantly, with a share of more than 25% during the projected period.

Previous Post

Novel Therapy Uses Blood Cells of Patients To Fight Tumour

Next Post

Elevating Vaccine Stability Through Predicting mRNA Degrades

Related Posts

WuXi Biologics and Virogen Bio partner to advance VG712
News

WuXi Biologics and Virogen Bio partner to advance VG712

19th June 2025
Construction of WuXi Biologics Microbial Manufacturing Site
News

Construction of WuXi Biologics Microbial Manufacturing Site

19th June 2025
Beyfortus From Sanofi to Make Imprint in 2025 26 RSV Season
News

Beyfortus From Sanofi to Make Imprint in 2025-26 RSV Season

19th June 2025
Thermo-Fischer-Accelerator Drug Development an Ideal Choice
News

Thermo Fischer Accelerator Drug Development an Ideal Choice

19th June 2025
IQVIA Custom Built AI Agents for Life Sciences Healthcare
News

IQVIA Custom-Built AI Agents for Life Sciences, Healthcare

19th June 2025
SCHOTT Pharma Invests
News

SCHOTT Pharma Invests EUR 100 Million in RTU Cartridges

9th June 2025
Next Post

Elevating Vaccine Stability Through Predicting mRNA Degrades

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Articles
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In